Abstract: In 2017, Jiangsu province has stepped forward in the reform of drug review and approval system, with equal importance attached to encouraging innovation in drug research and development and improving the quality and efficacy of generic drugs. The capability in research and development of pharmaceutical products has been further improved, with unexpected rise in the research and development of biological products. Registration application present the characteristics of "lead in quantity and optimization in structure", and the number of applications and approvals continues to be at the leading position in the country.